Transplant Diagnostic Market By Application (Diagnostic, Research Application), By Products & Services (Reagents And Consumables, Instruments, Software And Services), Technology(Molecular Assays, Non-Molecular Assays), By End User (Hospitals And Transplant Centers, Commercial Service Providers, Research Laboratories And Academic Institutes), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jul 21, 2016

Key Findings


The global transplant diagnostic market is expected to grow with an impressive CAGRof 9.12% during the forecast period 2016-2022.


The growing number of cases of chronic disordersand organ failures such as- liver, pancreas, lungs, kidney, and heart that requires the organs to be relocated, and a need of the organ transplantation is driving the global transplant diagnostic market. The advancements in technology are also driving the transplant diagnostic market. As the continuous innovations and technological advancements in HLA typing is helping the transplant diagnostic market to grow at rapid rate, and it is one of the key driver of the global transplant diagnostic market. But, as the technologies are increasing; similarly, the cost of thetreatment for the HLA typing is increasing, and are acting as one of the major restraint for the transplant diagnostic market. Huge R&D investments is leading to innovation in technology and development of new products in HLA(Human Leukocyte Antigen) typing, along with the growing solid organs, soft tissues, and stem cell transplant procedure are the major drivers that are predicted to boost the global transplant diagnostic market. Increase in funding; research grants; and, increasing public-private investments are the key drivers of the market.On the other hand, NGS and PCR based devices are highly expensive limiting its expansive adoption, along with limited medical reimbursement for organ donation and transplantation procedure in many countries across the globe are the major restraints barring the market growth. High R&D investments by the key market players and the fast growing healthcare infrastructure in the emerging countries are opening new opportunities for the global transplant diagnostic market. Significant gap between number of organs donated and organs required, annually; and, lack of awareness among the patients are the major challengesfacing the market.


Market Segment Insight


The global transplant diagnostic market can be divided into four segments on the basis of application; productsand services; technology; and, end user. On the basis of application it is segmented into diagnostic application and research application. On the basis of products and services, it is segmented in reagents & consumables; instruments; and, software & services. On the basis of technology, the market issegmented into Molecular assays, having two sub segments, namely, PCR-based and Sequencing-based; and, Non-molecular assays, further divided into serological assays & MLC assays. On the basis of end user, the market is categorized into three segments such as- hospital & transplant centers; commercial service providers; and, research laboratories & academic institutes. The product& services segment is divided into three heads; of which, the software and service sub segment is to experience the fastest growth rate during the forecast period, in transplant diagnostic market. Similarly, the end user segment is categorized into four head, of which, the hospitals and transplant centers has dominated the market in 2014.


Regional Insight


On the basis of regional outlook,transplant diagnostic market is divided into North America, Europe, Asia Pacific, and Rest of the world. North America dominates the transplant diagnostic market in 2015. And, as the healthcare market is increasing continuously, along with the patient’s increasing affordability; the North America market is expected to lead the global transplant diagnostic market in the near future. In 2016, North America and Europe areanticipated to be the established market in transplanting diagnostic products. Asia Pacific is the fastest growing region due to the huge potential of the market with increasing geriatric population, growing awareness, and increasing affordability of expensive medical treatments due to rise in disposable per capita income in the region.A well-developed infrastructure in healthcare market in North America is also one of the reasons for its dominance in the transplant diagnostic market, in terms of revenue. It is expected that the North America will also hold the largest market share of transplant diagnostic markets in 2016.The growth in this region is also rising due to increasing R&D investment by some of the key market players in transplant diagnostic market. In 2015 Europe was the second largest regional market for thetransplant diagnostic.During the forecast period, it is expected that the Asia Pacific will experience the fastest growth in transplant diagnostic market. India and China is expected to have the largest base of geriatric population, globally. Moreover, the growing medical tourism industry in these countries has the availability of advanced healthcare treatments in a very low or cheaper cost that is expected to attract the target patients of Asia Pacific, in turn, further boosting the growth of the market.


Competitive Insights


Some of the key players of the industries areAbbott laboratories, Inc. (U.S.);Ad Sigma-Aldrich;Affymetrix, Inc. (U.S.); Bio-Rad Laboratories, Inc. (U.S.); F. Hoffmann-La-Roche Limited. (Switzerland); Illumina, Inc. (U.S.);Immucor, Inc. (U.S); Linkage Biosciences;Luminex Corporation. (U.S.);Olerup SSP AB (Sweden);Qiagen N.V. (Netherlands); Thermo Fisher Scientific, Inc. (U.S.); and, more. Acquisitions, joint-ventures, mergers, and new product developments are the major strategies adopted by key players to sustain in the market.

CHAP 1. METHODOLOGY & SCOPE 12
1.1. RESEARCH METHODOLOGY 12
1.2. RESEARCH SCOPE & ASSUMPTIONS 12
1.3. LIST OF DATA SOURCES 12


CHAP 2. EXECUTIVE SUMMARY 13
2.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET SUMMARY & KEY BUYING CRITERIA 13
2.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET OUTLOOK 13
2.3. MARKET SEGMENTATION ANALYSIS 13
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 13
2.5. GLOBAL TRANSPLANT DIAGNOSTIC MARKET VALUE CHAIN ANALYSIS 13
2.6. VENDOR LANDSCAPE 13


CHAP 3. GLOBAL TRANSPLANT DIAGNOSTIC MARKET 14
3.1. MARKET DRIVER ANALYSIS 14
3.2. MARKET RESTRAINT ANALYSIS 14
3.3. KEY OPPORTUNITIES 14
3.4. CHALLENGES 14


CHAP 4. INDUSTRY ANALYSIS 15
4.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET– PORTER’S FIVE FORCE MODEL 15
4.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET– PESTEL ANALYSIS 15
4.3. GLOBAL TRANSPLANT DIAGNOSTIC MARKET- GAP ANALYSIS 15


CHAP 5. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY APPLICATION 2012-2022 ($ MILLION) 16
5.1. GLOBAL TRANSPLANT APPLICATION MARKET BY DIAGNOSTIC 2012-2022 ($ MILLION) 16
5.2. GLOBAL TRANSPLANT MARKET BY RESEARCH APPLICATION 2012-2022 ($ MILLION) 16


CHAP 6. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY PRODUCTS & SERVICES 2012-2022 ($ MILLION) 17
6.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY REAGENTS AND CONSUMABLES 2012-2022 ($ MILLION) 17
6.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY INSTRUMENTS 2012-2022 ($ MILLION) 17
6.3. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SOFTWARE AND SERVICES 2012-2022 ($ MILLION) 17


CHAP 7. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY TECHNOLOGY 2012-2022 ($ MILLION) 18
7.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY MOLECULAR ASSAYS 2012-2022 ($ MILLION) 18
7.1.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY PCR BASED MOLECULAR ASSAYS 2012-2022 ($ MILLION) 18
7.1.1.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SEQUENCE-SPECIFIC PRIMER (SSP)-PCR 2012-2022 ($ MILLION) 18
7.1.1.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE (SSO)-PCR 2012-2022 ($ MILLION) 18
7.1.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SEQUENCING-BASED MOLECULAR ASSAYS 2012-2022 ($ MILLION) 18
7.1.2.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SANGER SEQUENCING 2012-2022 ($ MILLION) 18
7.1.2.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY NEXT-GENERATION SEQUENCIG (NGS) 2012-2022 ($ MILLION) 18
7.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY NON-MOLECULAR ASSAYS 2012-2022 ($ MILLION) 18
7.2.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SEROLOGICAL ASSAYS 2012-2022 ($ MILLION) 18
7.2.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY MIXED LYMPHOCYTE CULTURE (MLC) ASSAYS 2012-2022 ($ MILLION) 18


CHAP 8. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY END USER 2012-2022 ($ MILLION) 19
8.1. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY HOSPITALS AND TRANSPLANT CENTERS 2012-2022 ($ MILLION) 19
8.2. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY COMMERCIAL SERVICE PROVIDERS 2012-2022 ($ MILLION) 19
8.3. GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 2012-2022 ($ MILLION) 19


CHAP 9. GLOBAL TRANSPLANT DIAGNOSTIC MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 20
9.1. NORTH AMERICA 20
9.1.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
9.1.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
9.1.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 20
9.1.3.1. U.S. 20
9.1.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
9.1.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
9.1.3.2. CANADA 20
9.1.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
9.1.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
9.2. EUROPE 20
9.2.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
9.2.2. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
9.2.3. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 20
9.2.3.1. GERMANY 20
9.2.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.2.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.2.3.2. UK 21
9.2.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.2.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.2.3.3. FRANCE 21
9.2.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.2.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.2.3.4. SPAIN 21
9.2.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.2.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.2.3.5. REST OF EUROPE 21
9.2.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022 ($ MILLION) 21
9.2.3.5.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.3. ASIA PACIFIC 21
9.3.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.3.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.3.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 21
9.3.3.1. CHINA 21
9.3.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.3.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.3.3.2. INDIA 22
9.3.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.3.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.3.3.3. JAPAN 22
9.3.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.3.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.3.3.4. OTHERS 22
9.3.3.4.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022 ($ MILLION) 22
9.3.3.4.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.4. MIDDLE EAST & AFRICA 22
9.4.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.4.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.5. LATIN AMERICA 22
9.5.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.5.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.5.2.1. BRAZIL 22
9.5.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 23
9.5.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 23


CHAP 10. COMPETITIVE LANDSCAPE 24
10.1. ABBOTT LABORATORIES, INC. (U.S.) 25
10.1.1. COMPANY OVERVIEW 25
10.1.2. FINANCIAL PERFORMANCE 25
10.1.3. PRODUCT BENCHMARKING 25
10.1.4. STRATEGIC INITIATIVES 25
10.2. AD SIGMA-ALDHRICH 25
10.2.1. COMPANY OVERVIEW 25
10.2.2. FINANCIAL PERFORMANCE 25
10.2.3. PRODUCT BENCHMARKING 25
10.2.4. STRATEGIC INITIATIVES 25
10.3. AFFYMETRIX, INC. (U.S.) 25
10.3.1. COMPANY OVERVIEW 25
10.3.2. FINANCIAL PERFORMANCE 25
10.3.3. PRODUCT BENCHMARKING 25
10.3.4. STRATEGIC INITIATIVES 25
10.4. BIO-RAD LABORATORIES, INC. (U.S.) 25
10.4.1. COMPANY OVERVIEW 25
10.4.2. FINANCIAL PERFORMANCE 25
10.4.3. PRODUCT BENCHMARKING 25
10.4.4. STRATEGIC INITIATIVES 25
10.5. F. HOFFMANN-LA-ROCHE LIMITED. (SWITZERLAND) 25
10.5.1. COMPANY OVERVIEW 25
10.5.2. FINANCIAL PERFORMANCE 25
10.5.3. PRODUCT BENCHMARKING 25
10.5.4. STRATEGIC INITIATIVES 25
10.6. ILLUMINA, INC. (U.S.) 25
10.6.1. COMPANY OVERVIEW 25
10.6.2. FINANCIAL PERFORMANCE 26
10.6.3. PRODUCT BENCHMARKING 26
10.6.4. STRATEGIC INITIATIVES 26
10.7. IMMUCOR, INC. (U.S) 26
10.7.1. COMPANY OVERVIEW 26
10.7.2. FINANCIAL PERFORMANCE 26
10.7.3. PRODUCT BENCHMARKING 26
10.7.4. STRATEGIC INITIATIVES 26
10.8. LINKAGE BIOSCIENCES 26
10.8.1. COMPANY OVERVIEW 26
10.8.2. FINANCIAL PERFORMANCE 26
10.8.3. PRODUCT BENCHMARKING 26
10.8.4. STRATEGIC INITIATIVES 26
10.9. LUMINEX CORPORATION. (U.S.) 26
10.9.1. COMPANY OVERVIEW 26
10.9.2. FINANCIAL PERFORMANCE 26
10.9.3. PRODUCT BENCHMARKING 26
10.9.4. STRATEGIC INITIATIVES 26
10.10. OLERUP SSP AB (SWEDEN) 26
10.10.1. COMPANY OVERVIEW 26
10.10.2. FINANCIAL PERFORMANCE 26
10.10.3. PRODUCT BENCHMARKING 26
10.10.4. STRATEGIC INITIATIVES 26
10.11. QIAGEN N.V. (NETHERLANDS) 26
10.11.1. COMPANY OVERVIEW 26
10.11.2. FINANCIAL PERFORMANCE 26
10.11.3. PRODUCT BENCHMARKING 26
10.11.4. STRATEGIC INITIATIVES 26
10.12. THERMO FISHER SCIENTIFIC, INC. (U.S.) 27
10.12.1. COMPANY OVERVIEW 27
10.12.2. FINANCIAL PERFORMANCE 27
10.12.3. PRODUCT BENCHMARKING 27
10.12.4. STRATEGIC INITIATIVES 27

TABLE 1 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 2 GLOBAL TRANSPLANT MARKET BY DIAGNOSTIC APPLICATION 2012-2022 ($ MILLION) 28
TABLE 3 GLOBAL TRANSPLANT MARKET BY RESEARCH APPLICATION 2012-2022 ($ MILLION) 28
TABLE 4 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY PRODUCTS 2012-2022 ($ MILLION) 28
TABLE 5 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY REAGENTS AND CONSUMABLES 2012-2022 ($ MILLION) 28
TABLE 6 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY INSTRUMENTS 2012-2022 ($ MILLION) 28
TABLE 7 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SOFTWARE AND SERVICES 2012-2022 ($ MILLION) 28
TABLE 8 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY TECHNOLOGY 2012-2022 ($ MILLION) 28
TABLE 9 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY MOLECULAR ASSAYS 2012-2022 ($ MILLION) 28
TABLE 10 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY PCR BASED MOLECULAR ASSAYS 2012-2022 ($ MILLION) 28
TABLE 11 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SEQUENCE-SPECIFIC PRIMER (SSP)-PCR 2012-2022 ($ MILLION) 28
TABLE 12 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE (SSO)-PCR 2012-2022 ($ MILLION) 28
TABLE 13 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SEQUENCING-BASED MOLECULAR ASSAYS 2012-2022 ($ MILLION) 28
TABLE 14 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SANGER SEQUENCING 2012-2022 ($ MILLION) 29
TABLE 15 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY NEXT-GENERATION SEQUENCIG (NGS) 2012-2022 ($ MILLION) 29
TABLE 16 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY NON-MOLECULAR ASSAYS 2012-2022 ($ MILLION) 29
TABLE 17 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY SEROLOGICAL ASSAYS 2012-2022 ($ MILLION) 29
TABLE 18 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY MIXED LYMPHOCYTE CULTURE (MLC) ASSAYS 2012-2022 ($ MILLION) 29
TABLE 19 GLOBAL TRANSPLANT DIAGNOSTIC MARKET BY END USER 2012-2022 ($ MILLION) 29
TABLE 20 GLOBAL TRANSPLANT DIAGNOSTIC HOSPITALS AND TRANSPLANT CENTERS MARKET 2012-2022 ($ MILLION) 29
TABLE 21 GLOBAL TRANSPLANT DIAGNOSTIC COMMERCIAL SERVICE PROVIDERS MARKET 2012-2022 ($ MILLION) 29
TABLE 22 GLOBAL TRANSPLANT DIAGNOSTIC RESEARCH LABORATORIES AND ACADEMIC INSTITUTES MARKET 2012-2022 ($ MILLION) 29
TABLE 23 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 24 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 29
TABLE 25 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 26 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 27 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 28 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 29 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 30 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 31 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 30
TABLE 32 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 33 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 34 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 35 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 36 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 37 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 38 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 39 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 40 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 41 RUSSIA MARKET ESTIMATES AND FORECAST2012-2022 ($ MILLION) 30
TABLE 42 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 43 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 44 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 30
TABLE 45 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 46 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 47 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 48 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
TABLE 49 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 31
TABLE 50 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
TABLE 51 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 31
TABLE 52 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022 ($ MILLION) 31
TABLE 53 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 31
TABLE 54 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
TABLE 55 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 31
TABLE 56 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
TABLE 57 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 31
TABLE 58 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
TABLE 59 BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 31

FIGURE 1 MARKET SHARE BY REGIONS 31
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 8 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 9 REST OF EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 10 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 11 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 12 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 13 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 14 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 15 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 16 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)